Research programme: cancer immunotherapeutics - Aduro/NovartisAlternative Names: CDNs - Aduro Biotech; LKZ 145
Latest Information Update: 29 Jun 2015
At a glance
- Originator Aduro BioTech
- Class Small molecules
- Mechanism of Action Immunomodulators; Protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer